Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Completed · Phase 2

Conditions studied: Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease

In brief

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Key facts

Study ID: NCT06948292
Run by: Ebima Clifford Okundaye
People needed: 127
Starts: 2023-03-01
Expected to finish: 2024-10-30
Last updated by the study team: 2025-09-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient with Chronic kidney disease stage 3-5
Estimated Glomerular function by MDRD of less than 60mls/min
Patients with declining renal function ( as measured by eGFR by MDRD )
Rate of decline of eGFR over the last one year of less than 20%
Negative Serology markers for CKD etiology
Provider perceived adherence to study follow- up

You may not qualify if…

Rapid rate of decline in kidney function of > 10 % over 3 months
Symptomatic renal failure
Presence of any suspected Acute renal failure superimposed
Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
No known reversible cause of renal decline

Where it is running

Neukidney Inc — Pasedena, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.